Neophore

Developer of small molecule therapies to treat cancer

placeCambridge, England, United Kingdom calendar_todayFounded 2017 groups10 employees language neophore.com

Registered entities

Innovation

13 patent families (2 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 604 times.

YearFilings
20172
20204
20213
20224
20237
20245
20253
20263

Social engagement

Social engagement: 3.2K social following, 7 posts in the last 12 months — below the industry typical range.

Investor mix

12 investors on record; lead investors include Claris Ventures, Sixth Element Capital.

Investor typeCountShare
Venture capital758%
Private equity18%
Other / undisclosed433%

Recent activity

17 Apr 2026
Recognition
9 Feb 2026
Recognition
27 Jan 2026
Event
DDR Inhibitors Summit
Coming soon